+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease

Blood 84(9): 3182-3188

Intracellular hemoglobin S (HbS) polymerization is most likely to be the primary determinant of the clinical and biologic manifestations of sickle cell disease (SCD). Fetal hemoglobin (HbF) does not enter the HbS polymer and its intracellular expression in sickle erythrocytes inhibits polymerization. HbF levels, high at birth but decreasing thereafter, protect the newborn from the clinical manifestations of this hemoglobinopathy. We have measured the sequential changes in HbF, F reticulocytes, and F cells in the first 2 years of life in 25 children with SCD and compared the results with those obtained in 30 normal children (AA). We have also calculated HbF per F cell (F/F cell), the preferential survival of F cells versus non-F cells, as measured by the ratio F cells versus F reticulocytes (FC/FR) and polymer tendency at 40% and 70% oxygen saturation. HbF levels decreased from about 80.4% +/- 4.0% at birth to 9.2% +/- 2.9% at 24 months. During this time, we observed a regular decrease of the F reticulocytes and the F cells. The kinetics of the decline of F/F cell was comparable with the decline of HbF, rapid from birth (mean, 27.0 +/- 3.6 pg) to 12 months of age (mean, 8.5 +/- 1.5 pg) and then slower from 12 to 24 months of age (mean, 6.2 +/- 1.0 pg) in the SCD children. In the AA children, the decrease in HbF, due to changes in both numbers of F cells and F/F cell, was more precipitous, reaching steady-state levels by 10 months of age. Calculated values for mean polymer tendency in the F-cell population showed that polymerization should begin to occur at 40% oxygen saturation at about 3 months and increase progressively with age, whereas polymerization at 70% oxygen saturation would not occur until about 24 months. These values correspond to HbF levels of 50.8% +/- 10.8% and 9.2% +/- 2.9%, respectively, and F/F cell levels of 15.6 +/- 4.5 pg and 6.2 +/- 1.0 pg, respectively. In the non--F-cell population, polymerization was expected at birth at both oxygen saturation values. Three individuals had significantly greater predicted polymerization tendency than the remainder of the group because of early decreases in HbF. These individuals in particular, the remainder of the cohort, as well as other recruited newborns, will be studied prospectively to ascertain the relationship among hematologic parameters, which determine polymerization tendency and the various clinical manifestations of SCD.

(PDF emailed within 1 workday: $29.90)

Accession: 010027613

Download citation: RISBibTeXText

PMID: 7524767

Related references

Cellular parameters of fetal hemoglobin response and predicted hemoglobin S polymerization in sickle cell children treated with hydroxyurea. Blood 84(10 SUPPL 1): 414A, 1994

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Red cell life span in sickle cell-hemoglobin C disease with a note about sickle cell-hemoglobin O ARAB. Blood 45(2): 273-279, 1975

Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. American Journal of Hematology 86(5): 430-432, 2011

The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood 58(6): 1057-1068, 1981

Enhanced Inhibition of Polymerization of Sickle Cell Hemoglobin in the Presence of Recombinant Mutants of Human Fetal Hemoglobin with Substitutions at Position 43 in the g-Chain. Biochemistry (American Chemical Society) 44(36): 188-95, 2005

Enhanced inhibition of polymerization of sickle cell hemoglobin in the presence of recombinant mutants of human fetal hemoglobin with substitutions at position 43 in the gamma-chain. Biochemistry 44(36): 12188-12195, 2005

Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. New England Journal of Medicine 325(16): 1150-1154, 1991

Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine 90(6): 372-378, 2012

Relationships between systemic vascular resistance, blood rheology and nitric oxide in children with sickle cell anemia or sickle cell-hemoglobin C disease. Clinical Hemorheology and Microcirculation 58(2): 307-316, 2015

Physiologic Decline in Fetal Hemoglobin Parameters in Infants With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 21(5): 407-411, 1999

Hematological change in sickle cell hemoglobin c disease and in sickle cell beta thalassemia a cohort study from birth. British Journal of Haematology 60(2): 279-292, 1985

Chemical heterogeneity of fetal hemoglobin in subjects with sickle cell anemia, homozygous Hb-C disease, SC disease, and various combinations of hemoglobin variants. Clinica Chimica Acta; International Journal of Clinical Chemistry 38(1): 5-16, 1972

The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Review of Hematology: 1-8, 2017

The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia. American Journal of Medical Genetics 27(3): 525-535, 1987